Sugi Predict

Sugi Predict / Compounds / SCHEMBL2590850

SCHEMBL2590850

SCHEMBL2590850

CCOC(=O)c1cc(C)c(C#N)c(OC)n1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ RECQL P46063 2/20 0.54
▸ KDM4E B2RXH2 8/20 0.46
▸ ALDH1A1 P00352 5/20 0.46
▸ HSD17B10 Q99714 4/20 0.46
▸ HPGD P15428 1/20 0.46
▸ GLA P06280 1/20 0.46
▸ ATM Q13315 1/20 0.46
▸ MAPT P10636 2/20 0.45
▸ KMT2A Q03164 1/20 0.45
▸ CYP1A2 P05177 1/20 0.43
▸ L3MBTL1 Q9Y468 5/20 0.43
▸ TP53 P04637 2/20 0.42
▸ GAA P10253 1/20 0.42
▸ ALOX15 P16050 1/20 0.42
▸ APOBEC3G Q9HC16 1/20 0.42
▸ HTT P42858 1/20 0.42
▸ TDP1 Q9NUW8 1/20 0.42
▸ MAPK8 P45983 2/20 0.41
▸ MAPK9 P45984 2/20 0.41
▸ TSHR P16473 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19068769 0.87 RECQL (0.58) RECQLKDM4EALDH1A1HSD17B10HPGD
SCHEMBL2592807 0.82 RECQL (0.59) RECQLKDM4EALDH1A1HSD17B10HPGD
SCHEMBL16401445 0.78 KDM4E (0.66) KDM4EALDH1A1HSD17B10HPGDGLA
SCHEMBL29496168 0.74 ALDH1A1 (0.48) RECQLKDM4EALDH1A1HSD17B10HPGD
SCHEMBL21847884 0.74 ALDH1A1 (0.48) RECQLKDM4EALDH1A1HSD17B10HPGD
SCHEMBL6137034 0.72 CA12 (0.55) KDM4EALDH1A1HSD17B10HPGDGLA
SCHEMBL2673753 0.72 RECQL (0.71) RECQLKDM4EALDH1A1HSD17B10HPGD
SCHEMBL2592972 0.72 RECQL (0.61) RECQLKDM4EALDH1A1HPGDCYP1A2
SCHEMBL2592865 0.71 MAPK8 (0.59) RECQLALDH1A1HPGDCYP1A2GAA
SCHEMBL2594001 0.71 RECQL (0.52) RECQLKDM4EALDH1A1HSD17B10HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10478426-B2 Enhancer of Zeste Homolog 2 inhibitors GLAXOSMITHKLINE LLC (US) 2019-11-19 — — US disclosed
US-20180207144-A1 ENHANCER OF ZESTE HOMOLOG 2 INHIBITORS GLAXOSMITHKLINE LLC 2018-07-26 — — US disclosed
US-9956210-B2 Enhancer of zeste homolog 2 inhibitors GLAXOSMITHKLINE LLC (US) 2018-05-01 — — US disclosed
EP-3246027-A1 INDOLE DERIVATIVES FOR THE TREATMENT OF CANCER GlaxoSmithKline LLC (US) 2017-11-22 — — EP disclosed
US-9695166-B2 Pyrazolopyridine pyrazolopyrimidine and related compounds GLOBAL BLOOD THERAPEUTICS, INC. (US) 2017-07-04 — — US disclosed
US-9695166-B2 Pyrazolopyridine pyrazolopyrimidine and related compounds GLOBAL BLOOD THERAPEUTICS, INC. (US) 2017-07-04 — — US disclosed
US-9695166-B2 Pyrazolopyridine pyrazolopyrimidine and related compounds GLOBAL BLOOD THERAPEUTICS, INC. (US) 2017-07-04 — — US disclosed
US-9649307-B2 Indoles GLAXOSMITHKLINE LLC (US) 2017-05-16 — — US disclosed
US-20170095461-A1 ENHANCER OF ZESTE HOMOLOG 2 INHIBITORS GLAXOSMITHKLINE LLC 2017-04-06 — — US disclosed
US-9562041-B2 Enhancer of zeste homolog 2 inhibitors GLAXOSMITHKLINE LLC (US) 2017-02-07 — — US disclosed
US-20130345200-A1 INDOLES GLAXOSMITHKLINE LLC (US) 2013-12-26 — — US disclosed
WO-2013173441-A2 ENHANCER OF ZESTE HOMOLOG 2 INHIBITORS GLAXOSMITHKLINE LLC (US) 2013-11-21 — — WO disclosed
EP-2646020-A1 INDOLES GlaxoSmithKline LLC (US) 2013-10-09 — — EP disclosed
US-20130245016-A1 INDOLES GLAXOSMITHKLINE LLC 2013-09-19 — — US disclosed
US-8536179-B2 Indoles GLAXOSMITHKLINE LLC (US) 2013-09-17 — — US disclosed
WO-2013067296-A1 METHOD OF TREATMENT GLAXOSMITHKLINE INTELLECTUAL PROPERTY (No 2) LIMITED (GB) 2013-05-10 — — WO disclosed
EP-2566327-A1 INDOLES GlaxoSmithKline LLC (US) 2013-03-13 — — EP disclosed
US-20130053397-A1 INDOLES GLAXOSMITHKLINE LLC 2013-02-28 — — US disclosed
WO-2012075080-A1 INDOLES GLAXOSMITHKLINE LLC (US) 2012-06-07 — — WO disclosed
WO-2011140324-A1 INDOLES GLAXOSMITHKLINE LLC (US) 2011-11-10 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130245016-A1 INDOLES IDO1, IDO2, INMT RECQL 1489/4885KDM4E 1312/4885ALDH1A1 38/4885
US-20180207144-A1 ENHANCER OF ZESTE HOMOLOG 2 INHIBITORS EZH2, EZH1, BMI1 RECQL 3966/4885KDM4E 43/4885ALDH1A1 1092/4885
US-20170095461-A1 ENHANCER OF ZESTE HOMOLOG 2 INHIBITORS EZH2, EZH1, BMI1 RECQL 3966/4885KDM4E 43/4885ALDH1A1 1092/4885
US-10478426-B2 Enhancer of Zeste Homolog 2 inhibitors EZH2, EZH1, BMI1 RECQL 3966/4885KDM4E 43/4885ALDH1A1 1092/4885
US-20130345200-A1 INDOLES IDO1, IDO2, INMT RECQL 1489/4885KDM4E 1312/4885ALDH1A1 38/4885
US-20130053397-A1 INDOLES IDO1, IDO2, INMT RECQL 1597/4885KDM4E 1253/4885ALDH1A1 45/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.